RealFeedApp Novo Nordisk raises profit and sales outlook
Revenue from the Wegovy pill reached 5.39 billion Danish kroner, exceeding analyst estimates. Consequently, Novo Nordisk updated its outlook for adjusted sales and operating profit growth to a maximum of 2%.
- Field
- drugs and trials
- What they did
- Novo Nordisk raised its profit and sales outlook for the year after reporting revenue of 5.39 billion Danish kroner from its Wegovy pill, which exceeded analyst estimates.
- Why it matters
- This provides a rare boost to the company, whose value has dropped by two-thirds since June 2024, helping it grow despite previous struggles to meet demand for its injectable GLP-1 brands.
#novo nordisk#wegovy#glp-1#sales forecast#profit
